Slava Akmaev is the Chief Technology Officer at Scipher Medicine. He is responsible for product development in precision medicine and early discovery efforts in drug development using the Network Medicine platform. He has been recognized as a leader in the adoption of the AI/ML technology in healthcare and drug development and is a frequent speaker at some of the most prolific industry events. Slava is the inventor on a number of issued and pending patent applications and has published more than 30 peer-reviewed articles in computational biology, artificial intelligence and molecular biology. Additionally, he authored book chapters and numerous scientific presentations and posters.
Formerly, Slava was the SVP and Chief Analytics Officer at Berg and the head of Berg Diagnostics and Analytics divisions where he has spent 7 years developing data driven technologies for target discovery and precision medicine. Before Berg, Dr. Akmaev was the Vice President of Scientific Affairs at GNS Healthcare and the Scientific Associate Director at Genzyme Genetics where he launched multiple commercial diagnostic products. At the beginning of his career he was a bioinformatics lead at Genzyme R&D where he developed novel statistical approaches for high-throughput “omics” data. Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder.
Chief Digital Health Physician, MITRE Corportation
Dr. Brian Anderson is a Harvard trained physician-scientist, digital health innovator and clinical systems engineer. Dr. Anderson became a nationally recognized expert on the use of information technology in support of emerging CDS models and the provision of safe, effective, patient-centered care while at Athena Health where he launched a new model of clinical decision support leveraging artificial intelligence. Dr. Anderson has also helped to develop and bring to market nascent technology and clinical workflows to support health system strategies around improved Patient Access. He has served on several national health information technology committees in partnership with the Office of the National Coordinator (ONC). Previously, Dr. Anderson led the Informatics Department at Athena Health where he focused his EHR product development around CDS systems.
As MITRE’s Chief Digital Health Physician, Dr. Anderson helps to architect, implement, and analyze health information systems for CMS, HHS, the FDA and the VA. Dr. Anderson is also the Co-Principal Investigator of MITRE’s largest internally funded R&D project, where he is leading the development of a common data model in Oncology based on FHIR, termed mCODE (minimal Common Oncology Data Elements). Dr. Anderson trained at Massachusetts General Hospital and also practiced at Greater Lawrence Family Medicine. He received his MD with honors from Harvard Medical School, and a BA in Social Anthropology, cum laude from Harvard University. Dr. Anderson regularly speaks at conferences on topics in Digital Health, and the development of machine learning tools to help deliver improved clinical care and analytical insight. He has multiple publications on topics related to digital health, precision medicine and RWD strategies for Oncology. Dr. Anderson has a passion for working at the intersection of technology, evidence-based medicine, predictive analytics and healthcare. Currently he lives in the greater Boston area, with his wife and 3 children.
Precision Medicine Informatics and Real-World Data Program Lead, XIFIN
Lori Anderson is product marketing manager for precision medicine informatics at XIFIN, where she brings many years of experience in medical affairs and product portfolio management in the healthcare and life-sciences industries. Prior to joining XIFIN, Lori was the director of health economics and outcomes research at Quest Diagnostics where she defined the reimbursement strategy for numerous tests routinely used in precision medicine. As a laboratorian herself with a particular interest in hematological neoplasms and the role of platelets in cardiovascular disease, Lori has contributed to the publication of 10 book chapters, 20 peer reviewed publications and over 40 poster presentations and has presented on numerous topics in laboratory medicine and life sciences worldwide.
Kristine Ashcraft, BS, MBA is a molecular biologist by training and is CEO and founder of YouScript. She has worked in the precision medicine space since 2000 and was recently named one of the 25 leading voices in precision medicine. Kristine has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications at an AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at SXSW, ASHG, and numerous precision medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine.
Chief, Division of Surgical Oncology, Brigham & Women’s Hospital at Brigham and Women’s/Dana Farber Cancer Center, Professor of Surgery, Harvard Medical School
Dr. Bertagnolli is the Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology at Harvard Medical School, and a member of the Gastrointestinal Cancer and Sarcoma Disease Centers at Dana-Farber/Brigham & Women’s Cancer Center, where she collaborates with colleagues in medical oncology, radiation oncology, and pathology to treat cancer patients in a tertiary care setting.
Dr. Bertagnolli graduated from Princeton University, and attended medical school at the University of Utah. She trained in surgery at Brigham and Women’s Hospital, and was a research fellow at the Dana Farber Cancer Institute (DF/BWCC). Dr. Bertagnolli has a background in laboratory work focusing upon understanding the role of the inflammatory response in epithelial tumor formation. From 1994-2011, she led gastrointestinal correlative science initiatives within the National Cancer Institute (NCI)-funded Cancer Cooperative Groups, where she facilitated integration of tumor-specific molecular markers of treatment outcome into nation-wide clinical cancer treatment protocols. From 2007-2018, Dr. Bertagnolli served as the Chief of the Division of Surgical Oncology at DF/BWCC. Dr. Bertagnolli has also had numerous leadership roles in multi-institutional cancer clinical research consortia, and currently serves as the Group Chair of the Alliance for Clinical Trials in Oncology, a nation-wide NCI-funded clinical trials group. She is also the Chief Executive Officer of Alliance Foundation Trials, LLC, a not-for-profit corporation that conducts international cancer clinical trials. In addition, Dr. Bertagnolli is the 2018-2019 Chair of the Board of Directors of the American Society of Clinical Oncology, a 45,000 member organization serving the needs of physicians and other clinicians who care for patients with cancer.
Senior Vice President, Market Access and Reimbursement, HeartFlow
Heather is a passionate professional that has worked within diagnostic medical imaging startups for over 15 years. Applying her software development and program management skills, she led a disciplined effort to earn a positive BCBS Evidence Street review, CMS New Technology APC payment classifications, Category III codes, and greater than 90% commercial coverage in 18 months for HeartFlow’s core technology, FFRct. Today, her leads her team to push the envelope on alternative payment models and value-based discussions with payers. Heather earned her Ph.D. in Biomedical Engineering from Vanderbilt University with a focus in neuroelectrophysiology.
An experienced healthcare executive with a proven track record of innovative value based reimbursement strategies, Lena Chaihorsky has spent her career studying reimbursement and the managed care industry from the perspective of diagnostics. With a background in biology and mathematics from Tufts, she has held leadership positions in sales, national contracting, and reimbursement for both start up and global diagnostics companies prior to co-Founding Alva10. Her thought leadership in payment innovation recently led to appointment on World Economic Forum working groups on Precision Medicine.
Dana is an accomplished and enthusiastic marketing professional with decades of experience in corporate marketing and publishing, membership, and partner/project management. After 25 years at National Geographic, she is now in a new career in the health and wellness arena at Inspire, the leading social network for health, who’s mission is to accelerate medical progress through a world of connected patients.
Outside of work, she is also focused on healthcare advocacy and policy. In addition to serving as an Executive Board Member of the Esophageal Cancer Action Network (ECAN), she is a Patient Representative on the Locally Advanced Esophageal Cancer Guideline Panel for the American Society of Clinical Oncology (ASCO) and serves on the GastroEsophageal Project Patient Advisory Committee, a project led by the Broad Institute of MIT and Harvard (a nonprofit academic research institution whose mission is to dramatically accelerate the understanding and treatment of disease).
Dana lives in Alexandria, VA, with her husband and three teenagers, and enjoys travel and walking and running outdoors.
Associate Director for Translational Science, Section Chief, Molecular Oncology, Omar Boraie Chair in Genomic Science, Professor of Medicine, Rutgers Cancer Institute
Dr. Ganesan came to The Cancer Institute of New Jersey in 2005 from the Dana-Farber Cancer Institute/Harvard Medical School where he was an instructor in medicine and staff physician. He received medical training at Yale University, where he graduated from with both an MD and a PhD in cell biology. Dr. Ganesan completed a medical residency at the Brigham and Women’s Hospital in Boston and served as a Chief Medical Resident and was followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute.
With a research interest in breast cancer biology and DNA repair, Dr. Ganesan is currently exploring how DNA repair defects in cancers can be exploited to develop novel effective treatments. He is also active in applying next-generation sequencing technology to identify specific genomic changes in cancers that can be therapeutically targeted. As a physician/scientist he runs a basic research laboratory focused on breast cancer biology and sees patients in the Stacy Goldstein Breast Cancer Center. In the clinic, Dr. Ganesan works collaboratively with experts across multi-disciplines and has the opportunity to put theory into practice as he aims to develop the next generation of targeted treatments for breast cancer. Working with a team of radiation oncologists, surgical oncologists, nurses, social workers, genetic specialists and others, he helps patients understand their specific disease and their treatment options so they can make informed decisions. He also is a critical driver of the Precision Medicine Initiative at the Cancer Institute and has developed a research protocol in which patients with rare or difficult to treat cancers under targeted genomic sequencing search for new potential treatment options. He has been instrumental in developing the Molecular Tumor Board at RCINJ and the new Molecular Therapeutics Clinic at Rutgers CINJ. This work has led to several novel findings that are driving both clinical trials and basic cancer research at the Cancer Institute. Dr. Ganesan is a Professor of Medicine and Pharmacology at Rutgers-Robert Wood Johnson Medical School, holds the Omar Boraie Chair in Genomic Science and serves as Associate Director for Translational Science at the Rutgers Cancer Institute of New Jersey. He is the author or co-author of more than 104 publications and serves on the editorial board of the journal Frontiers in Molecular and Cellular Oncology. Clinical expertise includes breast cancer, BRCA1/2, triple-negative breast cancer, breast cancer biology, rare cancers.
Hero Award, Triple Negative Breast Cancer Foundation, 2016
AHEPA, Axios Award, AHEPA 5Th District Cancer Research Foundation, 2015
Award of Hope for Leadership in Research and Patient Care, Rutgers Cancer Institute New Jersey, 2014
Tony Grover brings over 20 years of experience and expertise in business development, strategic partnerships, licensing, reimbursement and new technology platform development as an executive in the diagnostic and medical device industries. Tony has raised over $100M in cumulated capital, negotiated a variety of deals including licenses, strategic investment, joint ventures, and lab service agreements.
Most recently, Tony served as Vice President of Business Development for Banyan Biomarkers, where he was accountable for commercial activities in the US and global markets. Under his leadership, the company received the first FDA approval for a blood test to diagnose mild TBI, or concussion. Prior to Banyan Biomarkers, he was the Director of Marketing and Reimbursement at PhotoThera, a privately held medical device company developed a non-invasive laser for the treatment of ischemic stroke. Tony was also a management consultant for PRTM, now PwC, where he worked with a variety of Fortune 500 companies to increase operational efficiency.
Tony is the current Chairman of the BIOCOM Medical Device and Diagnostics Committee and on the Advisory Board of the Global Brain Health Coalition. He previously served as Chairman on the Board of Directors for the American Heart Association, San Diego. Tony is a Ronald E. McNair Scholar from Michigan State University with a B.S. in Biochemistry and has a M.B.A. from Carnegie Mellon University, Tepper School of Business.
Patricia Goede is VP Clinical Informatics at XIFIN, Inc., where she brings 22 years’ experience developing biomedical imaging informatics solutions and technology to facilitate multi-modality and multispecialty image-based exchange, collaboration, and management in distributed environments. Goede founded VisualShare and served as CEO until its acquisition by XIFIN in 2015. Previously, Goede was at the University of Utah where she pioneered a number of image, visualization and collaboration tools. She is the founder of the Electronic Medical Education Resource Group (EMERG), and as its director, established the Utah Center of Excellence for Electronic Medical Education. Goede holds an MS in Computational Visualization and a PhD. in Biomedical Imaging Informatics.
Senior Director, Global Strategic Partnerships, Life Sciences Solutions, Thermo Fisher Scientific
Madhushree Ghosh heads Global Strategic Partnerships within Thermo Fisher Scientific’s Clinical Sequencing Division, working closely with reference laboratories, global clinical research organizations, hospitals and heading alliance management of CDx pharma partnerships. Previously, she has held executive leadership roles at AltheaDx as the Vice President of Research Services, North America Head of R&D at QIAGEN, and Head of Product Development at Enigma Diagnostics. Madhu has led commercial adoption and product development programs for successful regulated product launches in oncology, infectious diseases and women’s health programs including Oncomine™ Dx Target Test, Ion Torrent Genexus System, and QIAGEN’s careHPV Test Kit. She has a PhD from University of Maryland, College Park in Biochemistry and completed her post-doctoral fellowship at Johns Hopkins University. Madhu’s accomplishments include multiple peer-reviewed publications and six issued patents in assay development and sample-to-answer medical devices; she is also passionate about empowering and promoting women into life sciences leadership roles.
Mark Hiatt, currently Vice President for a precision oncology company, has served as the Chief Medical Executive for a multi-state Blues plan and a National Medical Benefits Manager, and Department Leader and Board Member for a regional health system. Dr. Hiatt completed a fellowship in cardiovascular imaging at Stanford University, residency in radiology and master’s in Health Evaluation Sciences at the University of Virginia, and MD and MBA with academic distinction at Wake Forest University. He is the Chair of the Greater Salt Lake Chapter of the American Red Cross.
Principal Strategic Technologist, Kaiser Permanente
Arthur is a Principal Strategic Technologist at Kaiser Permanente, an organization that provides all insurance, hospital, and healthcare services to over 12 million members across the United States. He has over 19 years of experience in Health Information Technology, including Enterprise Architecture and development of the infrastructure for Service Oriented Architecture (SOA) – APIs, which move millions of messages per week at Kaiser Permanente. Most recently, Arthur has been focused on Precision Medicine strategies, data management, technology and the barriers to moving genomics into clinical care. He is a voting member of the HL7 Genomic Working Group. Arthur has been a Fellow to the World Economic Forum’s Precision Medicine team for the last 18 months.
Senior Director and Global Head, Translational Genomics, Q2 Solutions
Dr. Hurban is Senior Director and Global Head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes. Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.
Director, Massachusetts General Hospital Department of Medicine Innovation Program & Co-Founder, Dyrnamix, Inc.
Christiana Iyasere, MD, MBA, is a graduate of Yale College and Columbia University, College of Physicians and Surgeons. She completed her residency at Mass General in internal medicine in 2005. Following her tenure as a medical resident at Mass General, Dr. Iyasere undertook an administrative fellowship under the guidance of Dr. Peter Slavin, with an emphasis on technology evaluation, adoption and promotion. She subsequently went to Harvard Business School for continued management training and finished her degree in 2008. Since that 2008 Dr. Iyasere has been involved in the development of enterprise wide technology accelerators both for Partners Healthcare and Massachusetts General Hospital. She currently is the Director of the MGH Department of Medicine Innovation Program and is responsible for a portfolio of investments in therapeutics, informatics and digital health that have transformational potential in healthcare and is a co-founder of Dyrnamix, a cardiovascular diagnostics and informatic biotech.
Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross
As a Senior Research Analyst for Medical Policy and Technology Evaluation for Independence Blue Cross, Eugean Jiwanmall has served as subject-matter expert, writer, reviewer, communicator, presenter, consultant, adviser, facilitator, and decision maker for hundreds of medical policy topics and technology assessments spanning dozens of clinical disciplines and multiple business areas.
Eugean holds a bachelor’s in biological sciences with honors from Drexel University, master’s of public health in evaluative clinical sciences from Dartmouth Medical School, and MBA in healthcare management and economics with honors from Drexel University, and is completing graduate studies in bioethics at the University of Pennsylvania School of Medicine.
Chief Scientific Officer, N-of-One, a Qiagen Company
Sheryl Krevsky Elkin, PhD, is the Chief Scientific Officer at N-of-One, a QIAGEN company. An early member of the N-of-One team, Dr. Elkin has led the interpretation of thousands of patient cases, establishing a rigorous process for the analysis of scientific and clinical evidence and presentation of molecular and clinical evidence to physicians to help guide their therapeutic decisions. Dr. Elkin has taken a lead role in the development of the N-of-One clinical interpretation methodology to support clinicians in identifying therapeutic strategies specific to each patient. Prior to joining N-of-One, Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology’s Center for Cancer Research, where she earned a fellowship from the Leukemia and Lymphoma Society. She earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude, with High Distinction in Biology.
Daniel Lane, PharmD, PhD, MBA, collaborates with physicians, statisticians, data scientists and others both within and outside COTA to develop, conduct, and support research projects including observational studies, pharmacoeconomic analyses, and external control arms. Daniel also guides COTA’s strategy in both HEOR and RWE generation. Previously, Daniel served as the group director of real-world data/real-world evidence for US HEOR Oncology at Bristol-Myers Squibb.
Vice President, Market Access, Biotheranostics, Inc.
Debbie Ledet is the Vice President of Market Access with Biotheranostics, Inc. Debbie has spent the past 20 years successfully securing medical policy coverage and reimbursement for diagnostics and medical devices in start-ups and Fortune 500 companies including Cytyc/Hologic, Natera, Liposcience, Gambro and Johnson & Johnson Medical, Inc. She has held multiple Executive Leadership roles building and directing successful Market Access teams responsible for coding, coverage, contracting and reimbursement within Commercial and Governmental health plans. Debbie is an active coalition member within The Coalition for 21st Century Medicine, the American Clinical Laboratory Association (ACLA) and the California Clinical Laboratory Association (CCLA) sitting on various billing, reimbursement and public policy workgroups within these organizations. Debbie holds a Bachelor’s degree from the University of Memphis and resides in Charlotte, NC.
Vice Chair, CTCA Department of Medical Oncology, CTCA Philadelphia
Dr. Arturo Loaiza-Bonilla is the current Vice Chair of Medical Oncology of Research at Cancer Treatment Centers of America – ERMC, and also Co-Founder and Chief Medical Officer at Massive Bio (www.massivebio.com). A precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institutes of Health, his major interest focuses in the field of innovative approaches to match oncology patients to phase 1-3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient’s overall status under an Artificial Intelligence-based and machine learning platform, which integrates to the electronic medical record. His company and virtual tumor board / clinical trial matching platforms have been recently featured in GenomeWeb and MedPage Today, including a first-in-the-world registry, SYNERGY-AI to match cancer patients based on Artificial Intelligence (https://clinicaltrials.gov/ct2/show/NCT03452774)
Dr. Loaiza-Bonilla is Principal and co-investigator on several Phase I/III clinical trials in several malignancies at Cancer Treatment Centers of America, with emphasis in new targeted therapies, novel molecules and immunotherapy, tailored to specific tumor type, its genomics and protein expression profiles. He is also a passionate advocate for improved access to medical care, precision oncology, medical education, organized medicine leadership and health policy, having been awarded the ‘Top 40 Under 40’ award by the Philadelphia Business Journal, AMA Foundation Leadership Award, Fellowship of the American College of Physicians, and holding a Master in Medical Education (M.S.Ed) degree from the University of Pennsylvania. He has held several leadership positions in state and medical societies, including his current tenure as executive board member of the Pennsylvania Society of Oncology and Hematology, and his role as President of the Board of Directors of the Global Alliance for Patient Access.
Associate Vice President for Health Sciences and Chief Knowledge Officer, Executive Director, Center for Biomedical Informatics and Biostatistics, University of Arizona Health Sciences
Dr. Lussier is the Associate Vice President for Information Science and Chief Knowledge Officer of the UA Arizona Health Sciences (UAHS), Founding Director of the Center for Biomedical Informatics and Biostatistics, and Professor of Medicine. He received a bachelor of engineering and his medical degree from the University of Sherbrooke, Quebec, Canada. He performed predoctoral research in the Departments of Medicine and Human Physiology at the University of Sherbrooke and then completed an internship in ophthalmology at Laval University Hospital in Quebec City, and a residency in family medicine at the University of Sherbrooke Medical Center. He was a post-doctoral residential fellow in the Department of Biomedical Informatics in the College of Surgeons & Physicians at Columbia University. Dr. Lussier’s research group conducts pioneering hypothesis-driven computational modeling predictions in precision medicine that are then validated in vitro, in vivo and in clinical trials. As a leader of the fields of translational bioinformatics and of Data Science-augmented precision medicine, he has launched successful companies and international conferences, authored 185 publications, and delivered more than 100 invited presentations in precision medicine, systems medicine, and translational bioinformatics, including 21 opening keynotes at international conferences. He has been awarded $190,000,000 in grants as principal, core leader, or co-investigator, and mentored 53 graduate and postgraduate students as well as 40 junior faculty members. Dr. Lussier’s honors include three IBM Faculty Awards, inducted Fellow of the American College of Medical Informatics (ACMI), 1st recipient of the Columbia University Faculty Mentoring Award, “Ambassador for Health Sciences” at the University of Sherbrooke (Canada), and 16 outstanding publication awards from the American Medical Informatics Association (AMIA), the International Society for Computational Biology (ISCB), and the Translational Bioinformatics Conference (TBC). In 2016, Dr. Lussier was invited among ten USA academic leaders invited by the White House for its Precision Medicine Summit, where the University of Arizona Center for Biomedical Informatics and Biostatistics that he directs has committed $20M of R&D in bringing precision medicine to practice.Prior to joining COTA, Dr. Norden served as Deputy Chief Health Officer and lead physician for oncology and genomics at IBM Watson Health. He had previously worked at Dana-Farber Cancer Institute in Boston in several capacities, including Associate Chief Medical Officer, Medical Director of Satellites and Network Affiliates, and Assistant Professor of Neuro-Oncology.
Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare. Ms Mamuszka founded Alva10 after having spent almost 20 years in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Diagnostics are the key to Precision Medicine, but they need to be valued in the healthcare market in order to be successful. For years, diagnostics have been stuck in a downward cycle of value, with poor reimbursement leading to lack of investment, and lack of investment leading to sub-optimal clinical validation, leading back to poor reimbursement. Alva10 is changing that, bringing diagnostics to the forefront of Precision Medicine by partnering with payers and diagnostics companies using a proprietary algorithm to determine economic impact of diagnostics and create a new value based healthcare model.
Andrew Norden, MD, MPH, MBA, leads clinical strategy and execution at COTA. A renowned expert in real-world data and evidence and a sought after speaker and advisor on the topics, Dr.Norden is a trained neuro-oncologist, clinical researcher, and physician executive who joined COTA in 2017. Under his leadership, COTA built a scalable cancer-specific data model and approaches to clinical data curation and quality assurance that enable COTA’s provider and life sciences-facing applications. He is also responsible for COTA’s collaborative work with FDA, Friends of Cancer Research, and a number of additional partners.
Prior to joining COTA, Dr. Norden served as Deputy Chief Health Officer and lead physician for oncology and genomics at IBM Watson Health. He had previously worked at Dana-Farber Cancer Institute in Boston in several capacities, including Associate Chief Medical Officer, Medical Director of Satellites and Network Affiliates, and Assistant Professor of Neuro-Oncology.
Dr. Norden is the author of more than 65 peer-reviewed papers primarily involving therapy for high-grade gliomas and meningioma, is an active member of the American Society of Clinical Oncology, the American Medical Informatics Association, Society for Neuro-Oncology, and is an Associate Editor of JCO-Clinical Cancer Informatics.
Dr. Norden attended the Yale School of Medicine and earned an MPH degree from Harvard School of Public Health, an MBA from the University of Massachusetts, Amherst, and an undergraduate degree in neuroscience from Brown University.
David Parker, PhD, is Senior Vice President, Diagnostics Solutions at Precision for Medicine. He currently leads Precision for Medicine’s Diagnostics Solutions consulting practice and provides strategic advisory services to the firm’s diagnostics, device, and biopharma clients. David has well almost 35 years of experience in the healthcare industry, including 23 years of strategy consulting experience centered on the intersection of reimbursement, health economics, clinical science, and marketing strategy. His consulting encompasses all aspects of market access, reimbursement, evidence development strategy, and commercialization, with a particular focus on personalized medicine, advanced molecular and companion diagnostics, and targeted therapies.
Throughout his career, David’s expertise has resulted in numerous successful product launches, guided major investment and acquisition decisions, and driven favorable coverage and payment determinations by public and private payers alike. His consulting career was preceded by 11+ years of increasingly responsible product and marketing management, strategic planning, and business development roles at biotechnology companies ranging from development-stage to units of Fortune 500 businesses. David is a frequent speaker and the author of peer-reviewed publications as well as book chapters in the biomedical sciences and health economics.
David received his AB degree in Biochemistry with high honors from Princeton University and his PhD in Cell and Developmental Biology from the Massachusetts Institute of Technology, where he was a National Science Foundation fellow.
Henry Pickering Walcott Professor of Computational Biology and Bioinformatics
Chair, Department of Biostatistics, Harvard University T.H. Chan School of Public Health
John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John’s PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. John’s research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has made pioneering discoveries about how the genetic variants work together to determine our traits. John has published more than 280 papers; his work has been cited more than 65,000 times. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.
Sumanth currently functions as the EIR within the National Account division at Anthem and Chairman of his family office, Reddy Ventures. He is on the lookout for innovators that are like minded in the healthcare space that believe empathy and patient care should come 1st followed by profit and scale. He believes the future of healthcare delivery will be de-centralized through primary care, retail clinics and small footprint infrastructure where the foundational focus is on approachable and cost effective preventative and precision medicine platforms.
Sumanth transitioned mid-way from an accelerated BS/MD program at NEOMED in Ohio to running clinical trials in India for early/growth stage medical device companies. This led to advising the largest health system in India, Apollo Hospitals, on new ventures and technologies. Sumanth has been a co-founder/investor in multiple early stage medical devices/AI entities – all of which have exited either privately or publicly. The most notable being BioD (the 1st amniotic membrane to heal ocular surface disorders) exited to Derma Sciences and subsequently Integra LifeSciences. Before joining Anthem, he left healthcare briefly to focus on his family office – most notable portfolio company is Quantify Energy. Quantify Energy has a portfolio of energy efficiency technologies across electricity, water and gas yielding 10-30% savings with a payback of less than 2 years and an IRR of 45%+. Quantify has the quickest payback and highest IRR within the energy efficiency space confirmed by MIT and Dartmouth. Currently Quantify has implemented within 40+ of the Fortune 500 and 150+ of the Fortune 2000.
Wendy Rubinstein, MD, PhD, FACP, FACMG is Director of Personalized Medicine at FDA in the Center for Devices and Radiological Health. Dr. Rubinstein is a board-certified clinical geneticist and clinical molecular geneticist who directed academic cancer genetics programs for 15 years at three NCI-designated Comprehensive Cancer Centers. From 2011 to 2017 she was a Senior Scientist at the National Institutes of Health where she launched and directed the NIH Genetic Testing Registry (GTR) and ultimately served as Chief of Medical Genetics and Human Variation at the National Center for Biotechnology Information, hosting flagship information resources including ClinVar, dbSNP, dbGaP, GeneReviews, and GTR. Prior to joining FDA, Dr. Rubinstein was Deputy Medical Director of CancerLinQ, the American Society of Clinical Oncology’s real world data platform aimed at improving the quality of care for patients with cancer.
An NIH Medical Scientist Training Program scholarship awardee, Dr. Rubinstein earned her MD and PhD degrees at the Mount Sinai School of Medicine. She has authored publications on gene discovery (SDHD), variant interpretation, computerized familial risk assessment, pharmacogenomics, genetic risk modifiers, clinical practice guidelines, and health information technology.
Associate Chief Medical Officer, University of Utah Plans
Dr. Schaecher has been active in managed care for over 20 years initially involved in utilization management, credentialing, formulary management and appeals for several managed care organizations in the late 1990’s. Employed by Intermountain Healthcare/SelectHealth from 1998 until 2017 and subsequently by University of Utah Health Plans his responsibilities have included quality improvement, medical policy development/implementation, new technology assessment, assisted with benefit design, fee schedule development, fraud/waste/abuse, medical coding and auditing, provider relations liaison and value-based programs. Throughout this time he has worked closely with pharmacy services at both plans in developing the plan formulary and has been active in the Pharmacy and Therapeutics committee at the Plan and system level working to align formularies so as to reduce administrative complexity and cost yet assuring appropriate patient access to important therapies.
Prior to joining SelectHealth, Dr. Schaecher was Chief of Staff at Pioneer Valley Hospital and President of Granger Medical Clinic, the largest independent multispecialty clinic in the Salt Lake Valley. He is past President of the Salt Lake County Medical Society and is the past Chairman of the State of Utah Physician Licensing Board.
Dr. Schaecher is board certified in internal medicine and received his medical training at the University of South Dakota and the University of Utah. He has been a certified professional coder since 2012.
Clynt Taylor is the Chief Executive Officer of Intervention Insights and a member of the company’s board of directors. He joined Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.
Since beginning his career at IBM, he’s held leadership roles at healthcare technology companies like NextGen, where he led sales and marketing teams; HealthVision as General Manager of its fastest growing division (purchased by Lawson) and Galvanon as Co-founder and CEO Healthcare Solutions (purchased by NCR). Most recently, he held various senior executive roles with NantHealth – including leading the innovation, launch and commercialization of eviti, Inc., recognized today as one of the nation’s premier oncology decision support solutions. Clynt is married with four children and lives in the Dallas area.
At Dana-Farber Cancer Institute (DFCI) in Boston, MA, Carole Tremonti is the Senior Director of Dana-Farber Pathways Operations. In her role, she is responsible for the strategy, oversight, development and management of DFCI’s clinical Pathways program. Pathways are an electronic decision support tool which defines the singular most scientifically advanced treatment for a cancer condition. Carole’s priority is to create solutions which solve clinical problems, streamline provider workflow and improve the quality of patient care through the synergy of digital informatics solutions, clinical and scientific expertise. With measurement as a foundation, Ms. Tremonti identifies, develops and executes innovative solutions to improve the delivery of cancer care.
Head of Vital Program, Highmark Health & Chief Marketing Officer, NightWare
Matthew Tucker has been in healthcare for 20 years in commercial roles at startups and large multi-national companies such as Mylan, Baxter Healthcare, and Highmark Health. He has led brands and portfolios in medical devices and pharmaceuticals, as well as commercial programs such as Highmark’s Vital program. He also runs an independent consulting company helping medtech companies achieve commercial and customer success. He is the author of the book “The Selfish Career” and is on the Board of Directors of Facing Forward, a non-profit in Chicago working to end homelessness.
Chief Scientific Officer and Senior Vice President Medical Affairs, Genome Medical, Inc.
Huntington F. Willard, PhD, is Chief Scientific Officer and Senior Vice President for Medical Affairs at Genome Medical, Inc. He has deep experience in genetics and genomics leadership in academia, health care and industry, building teams that span research, education and clinical care. Prior to joining Genome Medical, Dr. Willard was most recently Director and Principal of National Precision Health at Geisinger Health in Maryland and Pennsylvania, with a focus on design and implementation of large-scale clinical and research programs in genomics and population screening. Dr. Willard is the author or co-author of more than 350 scientific publications and is co-editor of the Genomic and Precision Medicine book series and a longtime co-author of the textbook Genetics in Medicine. A former President of the American Society of Human Genetics, he is an elected member of the National Academy of Medicine and the National Academy of Sciences.
Head of Market Access, ExosomeDx, a Bio-Techne Brand
Debbie Windsor has 17 years in the health care landscape working with all channels within Health Care. She has worked with multiple levels of decision makers within including Hospitals, Physician Groups, Specialty Groups, IDN, Health Systems, Health Plans, and Lab Benefit Management. Debbie’s background helped her develop a deep understanding of clients and their needs and how to meet those needs with a consultative solution oriented approach. Working as Market Access Leader for five years has led her to a deep understanding of HEDIS/STAR ratings, Reimbursement and PAMA landscape, Technology, and Companion Diagnostics.
Vice President, General Manager, Genomics Laboratories
Kellie Yarnell is Vice President of Genomics Laboratories, where she leads the genomics efforts and organization. Previously, Kellie led genomic operations for Expression Analysis, an organization specializing in next-generation sequencing and bioinformatics services supporting the biopharmaceutical clinical trial and research market. Kellie brings more than 20 years of commercial expertise, scientific aptitude and strategic vision in the genomics space to the organization.
Kellie earned a Bachelor of Science in Biochemistry from the University of Delaware.